Home Cart Sign in  
Chemical Structure| 115841-09-3 Chemical Structure| 115841-09-3

Structure of Salvianolic acid C
CAS No.: 115841-09-3

Chemical Structure| 115841-09-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Salvianolic acid C, a natural product isolated and purified from the root of Salvia miltiorrhiza Bge. with antioxidant effect, exhibits potent XOD inhibitory activity with an IC(50) of 9.07 μM, and enhances the inhibitory effects on sEH might be efficient ways to improve its cardiovascular protective and anti-inflammatory effects.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Salvianolic acid C

CAS No. :115841-09-3
Formula : C26H20O10
M.W : 492.43
SMILES Code : O=C(O)[C@H](OC(/C=C/C1=C2C=C(C3=CC=C(O)C(O)=C3)OC2=C(O)C=C1)=O)CC4=CC=C(O)C(O)=C4
MDL No. :MFCD16660675
InChI Key :GCJWPRRNLSHTRY-VURDRKPISA-N
Pubchem ID :13991590

Safety of Salvianolic acid C

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HUVECs 4, 8, 16 µg/mL 24 hours Promote HUVECs migration Molecules. 2022 Jun 24;27(13):4075
HUVECs 2, 4, 8, 16, 32 µg/mL 24 hours Promote HUVECs proliferation Molecules. 2022 Jun 24;27(13):4075
ACE2-overexpressed HEK-293T cells 0.31 µM (IC50) 12 hours To assess the inhibitory effect of Salvianolic acid C on the entry of SARS-CoV-2 S protein-pseudo-typed virus into cells, results showed effective inhibition. Acta Pharmacol Sin. 2022 Apr;43(4):771-780.
HT22 cells 100 µM and 200 µM 14 hours To evaluate the protective effect of SalC on OGD/R injury, results showed that SalC significantly increased the survival rate of HT22 cells. Chin Med. 2024 Mar 11;19(1):46
Vero-E6 cells 0.97 µM (EC50) 24 hours To evaluate the antiviral activity of Salvianolic acid C against SARS-CoV-2, results showed significant antiviral effects. Acta Pharmacol Sin. 2022 Apr;43(4):771-780.
ACE2 high-expressing HEK293T cells (ACE2hcells) 0, 25, 50 µM 24 hours Evaluate the effect of Salvianolic acid C on apoptosis of ACE2h cells, showing an apoptosis rate of less than 10% at 50 μM. J Med Virol. 2021 May;93(5):3143-3151
ACE2 high-expressing HEK293T cells (ACE2hcells) 0, 25, 50, 100, 200, 400 µM 24 hours Evaluate the effect of Salvianolic acid C on the viability of ACE2h cells, showing minor effects on cell viability at concentrations below 100 μM. J Med Virol. 2021 May;93(5):3143-3151
Human liver microsomes 20 µM 60 minutes Evaluate the inhibitory effect of salvianolic acid C on rivaroxaban metabolism Front Pharmacol. 2022 Jul 19;13:950525
Rat liver microsomes 20 µM 60 minutes Evaluate the inhibitory effect of salvianolic acid C on rivaroxaban metabolism Front Pharmacol. 2022 Jul 19;13:950525
BV2 cells 100 µM and 200 µM 8 hours To evaluate the protective effect of SalC on OGD/R injury, results showed that SalC significantly increased the survival rate of BV2 cells. Chin Med. 2024 Mar 11;19(1):46

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague Dawley rats Cerebral ischemia/reperfusion injury model Intraperitoneal injection 20 mg/kg Once daily for 7 days To evaluate the protective effect of Salvianolic acid C on cerebral ischemia/reperfusion injury, results showed that Salvianolic acid C significantly reduced cerebral infarction volume and improved neurological deficit scores. Front Pharmacol. 2022 Jan 27;12:799448
C57BL/6J mice Transient middle cerebral artery occlusion (tMCAO) model Intraperitoneal injection 20 mg/kg and 40 mg/kg Once daily for 48 hours To evaluate the neuroprotective effect of SalC on tMCAO mice, results showed that SalC significantly reduced cerebral infarct volume, improved neurological deficits, and reversed pathological changes. Chin Med. 2024 Mar 11;19(1):46
Mice CD41-deficient mice Tail vein injection 40 µg/mL Single injection, observed at 2 hours and 24 hours To assess the effect of doxorubicin on platelet clearance, results showed that doxorubicin accelerated platelet clearance. Pharmaceuticals (Basel). 2022 Nov 22;15(12):1444
Wistar rats Oral glucose tolerance test model Oral 400 mg/kg Single dose, observed for 150 minutes Evaluate the antihyperglycemic activity of salvianolic acid C, results showed significant reduction in blood glucose levels, comparable to glibenclamide. Saudi Pharm J. 2024 Nov;32(11):102184
C57Bl/6j mice Pressure-overload model (TAC surgery) Intraperitoneal injection 5, 10 mg/kg Not specified To evaluate the therapeutic effect of salvianolic acid C on pressure-overload-induced cardiac fibrosis. Results showed that salvianolic acid C effectively reduced perivascular collagen deposition and alleviated left ventricular dysfunction and myocardial hypertrophy. Signal Transduct Target Ther. 2022 Sep 1;7(1):303

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.03mL

0.41mL

0.20mL

10.15mL

2.03mL

1.02mL

20.31mL

4.06mL

2.03mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories